UNSPSC 51272208: Tiletamine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C12H17NOS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99TAQ2QWJI, chemically known as cyclohexanone, 2- (ethylamino)-2-(2-thienyl)-, hydrochloride but more generally known as tiletamine hydrochloride, which bears US NIH Compound Identifier 26533. European Medicines Agency schedules Tiletamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04867MIG.

Most nations, for tariff and trade purposes, schedule tiletamine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, TILETAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tiletamine hydrochloride bears US NLM identifiers UMLS ID C0936267 and NCI Concept Code C84212. SMILES: CCNC1(CCCCC1=O)C2CCCS2.CL.

UNSPSC 51272208 Tiletamine hydrochloride is a Commodity code under which state and local procurement offices tag pharmaceutical purchases, though recent solicitation activity shows minimal direct procurement of this specific anesthetic compound. Instead, the code appears in state and local opportunities that address broader pharmaceutical sourcing — generic multi-source medications, naloxone and drug deactivation systems, and direct-to-manufacturer prescription programs that may encompass compounds in this class as part of wider formulary or emergency-response acquisitions. The actual buying activity under this code spans county health departments, state health and human services agencies, and multistate cooperative purchasing groups acquiring pharmaceuticals for community health initiatives, emergency medical response, and employee health benefit programs. Work is solicited through RFPs, RFQs, and RFIs that emphasize wholesale distribution partnerships, pricing transparency, cGMP and Drug Supply Chain Security Act compliance, and quarterly or ongoing delivery to health facilities and networked provider locations.

Recent opportunities cluster in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program supporting self-insured state employee health plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) to establish multiple-award contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract commencement July 1, 2026 and participation extending to Oregon. All three solicitations require vendor compliance with federal manufacturing and supply-chain standards, insurance coverage minimums, and electronic ordering or reporting capabilities.